| 1.89 -0.06 (-3.08%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.49 |
1-year : | 2.7 |
| Resists | First : | 2.13 |
Second : | 2.31 |
| Pivot price | 2.03 |
|||
| Supports | First : | 1.84 | Second : | 1.53 |
| MAs | MA(5) : | 1.94 |
MA(20) : | 2.06 |
| MA(100) : | 2.22 |
MA(250) : | 2.96 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20  |
D(3) : | 17.6 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 5.17 | Low : | 1.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRCE ] has closed above bottom band by 1.1%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.04 - 2.05 | 2.05 - 2.06 |
| Low: | 1.82 - 1.83 | 1.83 - 1.84 |
| Close: | 1.87 - 1.89 | 1.89 - 1.91 |
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Fri, 16 Oct 2026
Opaleye management, 10% owner, buys $136,177 Grace Therapeutics (GRCE) - Investing.com
Fri, 16 Oct 2026
Opaleye management, 10% owner, buys $136,177 Grace Therapeutics (GRCE) By Investing.com - Investing.com South Africa
Fri, 16 Oct 2026
A 10% owner buys Grace Therapeutics (GRCE) shares over three days, including 36,347 on October 16. - Stock Titan
Thu, 15 Oct 2026
Opaleye Management Inc. Adds 14,632 Shares of Grace Therapeutics Inc (GRCE) in Latest 13G Filing - GuruFocus
Tue, 13 Oct 2026
At $2.02 a share, Opaleye buys 7,215 shares of Grace Therapeutics (GRCE) - Stock Titan
Wed, 05 Aug 2026
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 18.6 (%) |
| Held by Institutions | 31.5 (%) |
| Shares Short | 1,720 (K) |
| Shares Short P.Month | 1,590 (K) |
| EPS | -1.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -36.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -1.62 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|